H Frankel1, S Byberg2, M Bjerregaard-Andersen3, C L Martins4, P Aaby5, C S Benn6, A B Fisker7. 1. Bandim Health Project, Indepth Network, Apartado 861, 1004 Bissau Codex, Guinea-Bissau; Research Center for Vitamins and Vaccines (CVIVA), Bandim Health Project Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark. Electronic address: hannah.frankel@gmail.com. 2. Bandim Health Project, Indepth Network, Apartado 861, 1004 Bissau Codex, Guinea-Bissau; Research Center for Vitamins and Vaccines (CVIVA), Bandim Health Project Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark; OPEN, Odense Patient data Explorative Network, Odense University Hospital/Institute of Clinical Research, University of Southern Denmark, Odense, Denmark. Electronic address: s.byberg@bandim.org. 3. Bandim Health Project, Indepth Network, Apartado 861, 1004 Bissau Codex, Guinea-Bissau; Research Center for Vitamins and Vaccines (CVIVA), Bandim Health Project Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark; Department of Endocrinology, Odense University Hospital, Odense, Denmark. Electronic address: mban@dadlnet.dk. 4. Bandim Health Project, Indepth Network, Apartado 861, 1004 Bissau Codex, Guinea-Bissau. Electronic address: c.martins@bandim.org. 5. Bandim Health Project, Indepth Network, Apartado 861, 1004 Bissau Codex, Guinea-Bissau; Research Center for Vitamins and Vaccines (CVIVA), Bandim Health Project Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark. Electronic address: p.aaby@bandim.org. 6. Bandim Health Project, Indepth Network, Apartado 861, 1004 Bissau Codex, Guinea-Bissau; Research Center for Vitamins and Vaccines (CVIVA), Bandim Health Project Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark; OPEN, Odense Patient data Explorative Network, Odense University Hospital/Institute of Clinical Research, University of Southern Denmark, Odense, Denmark. Electronic address: cb@ssi.dk. 7. Bandim Health Project, Indepth Network, Apartado 861, 1004 Bissau Codex, Guinea-Bissau; Research Center for Vitamins and Vaccines (CVIVA), Bandim Health Project Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark; OPEN, Odense Patient data Explorative Network, Odense University Hospital/Institute of Clinical Research, University of Southern Denmark, Odense, Denmark. Electronic address: abf@ssi.dk.
Abstract
BACKGROUND: Different Bacillus Calmette-Guerin (BCG) vaccine strains may have different non-specific effects. We assessed the effect of two BCG strains (Danish and Russian) on childhood morbidity and BCG scarification in Guinea-Bissau. METHODS: During 2011-2013, infants in the Bandim Health Project's urban study area received the Danish or Russian BCG in a natural experiment. Health center consultations were registered at point of care and scar status and size at age 4½ months. We assessed the effect of strain on consultation rates between vaccination and age 45days in Cox proportional hazards models. Scar prevalence and size were compared using binomial regression and ranksum tests. RESULTS: Among 1206 children, 18% received Danish BCG (n=215) and 82% Russian BCG (n=991). The adjusted hazard ratio (aHR) for consultations was 0.94 (95% CI 0.60-1.46) for Danish BCG compared with Russian BCG. Girls vaccinated with Danish BCG tended to have lower consultation rates compared with girls vaccinated with Russian BCG (aHR 0.56 (0.25-1.24)), whereas the effect was opposite for boys (aHR 1.24 (0.74-2.11)), p=0.09. Children vaccinated with Danish BCG were more likely to develop a scar (97%) than children vaccinated with Russian BCG (87%), the relative risk (RR) being 1.11 (1.06-1.16). The effect was stronger in girls, and BCG scar size was larger among infants vaccinated with the Danish strain. CONCLUSION: BCG strain influences scar prevalence and scar size, and may have sex differential effects on morbidity. BCG strains are currently used interchangeably, but BCG scarring has been linked to subsequent survival. Hence, more research into the health effects of different BCG strains is warranted. Small adjustments of BCG production could potentially lower childhood morbidity and mortality at low cost.
BACKGROUND: Different Bacillus Calmette-Guerin (BCG) vaccine strains may have different non-specific effects. We assessed the effect of two BCG strains (Danish and Russian) on childhood morbidity and BCG scarification in Guinea-Bissau. METHODS: During 2011-2013, infants in the Bandim Health Project's urban study area received the Danish or Russian BCG in a natural experiment. Health center consultations were registered at point of care and scar status and size at age 4½ months. We assessed the effect of strain on consultation rates between vaccination and age 45days in Cox proportional hazards models. Scar prevalence and size were compared using binomial regression and ranksum tests. RESULTS: Among 1206 children, 18% received Danish BCG (n=215) and 82% Russian BCG (n=991). The adjusted hazard ratio (aHR) for consultations was 0.94 (95% CI 0.60-1.46) for Danish BCG compared with Russian BCG. Girls vaccinated with Danish BCG tended to have lower consultation rates compared with girls vaccinated with Russian BCG (aHR 0.56 (0.25-1.24)), whereas the effect was opposite for boys (aHR 1.24 (0.74-2.11)), p=0.09. Children vaccinated with Danish BCG were more likely to develop a scar (97%) than children vaccinated with Russian BCG (87%), the relative risk (RR) being 1.11 (1.06-1.16). The effect was stronger in girls, and BCG scar size was larger among infants vaccinated with the Danish strain. CONCLUSION:BCG strain influences scar prevalence and scar size, and may have sex differential effects on morbidity. BCG strains are currently used interchangeably, but BCG scarring has been linked to subsequent survival. Hence, more research into the health effects of different BCG strains is warranted. Small adjustments of BCG production could potentially lower childhood morbidity and mortality at low cost.
Authors: Francesca Schiaffino; Gwenyth O Lee; Maribel Paredes-Olortegui; Lilia Cabrera; Pablo Penataro-Yori; Robert H Gilman; Margaret N Kosek Journal: Am J Perinatol Date: 2018-12-24 Impact factor: 1.862
Authors: Katarina M Funch; Sanne M Thysen; Amabelia Rodrigues; Cesario L Martins; Peter Aaby; Christine S Benn; Ane B Fisker Journal: Hum Vaccin Immunother Date: 2018-01-23 Impact factor: 3.452
Authors: S H Pennington; D M Ferreira; E Caamaño-Gutiérrez; J Reiné; C Hewitt; A D Hyder-Wright; S B Gordon; M A Gordon Journal: Sci Adv Date: 2019-02-27 Impact factor: 14.136
Authors: Sanne M Thysen; Aksel Karl Georg Jensen; Amabelia Rodrigues; Igualdino da Silva Borges; Peter Aaby; Christine Benn; Ane Fisker Journal: BMJ Open Date: 2019-09-24 Impact factor: 2.692
Authors: Nicole L Messina; Kaya Gardiner; Susan Donath; Katie Flanagan; Anne-Louise Ponsonby; Frank Shann; Roy Robins-Browne; Bridget Freyne; Veronica Abruzzo; Clare Morison; Lianne Cox; Susie Germano; Christel Zufferey; Petra Zimmermann; Katie J Allen; Peter Vuillermin; Mike South; Dan Casalaz; Nigel Curtis Journal: BMJ Open Date: 2019-12-15 Impact factor: 2.692
Authors: Niyati Lobo; Nathan A Brooks; Alexandre R Zlotta; Jeffrey D Cirillo; Stephen Boorjian; Peter C Black; Joshua J Meeks; Trinity J Bivalacqua; Paolo Gontero; Gary D Steinberg; David McConkey; Marko Babjuk; J Alfred Witjes; Ashish M Kamat Journal: Nat Rev Urol Date: 2021-06-15 Impact factor: 14.432